Two of Myriad Genetics and OncorMed, competed to develop a genetic test for breast tenderness and ovarian cancer. Although the two companies offer genetic testing for women who participated in the study, in 1995, both have been considering selling its testing services for physicians in general. Despite the promising market for this testing service, some scientists and patient groups activist believes that it would be premature to provide testing is carefully controlled research environment, where data can be collected on a regular basis to answer important questions about the health consequences of genetic mutations and the potential benefits and risks of testing. In particular, they argued that commercialization should wait, because the knowledge about genetic susceptibility to breast cancer is still there, and health care options for mutation carriers is limited and no proven benefit. In addition, data on the psychological and social consequences for women who have been tested is still evolving. Those in favor of the limitations of such testing to the study setting wanted laws to protect people from irresponsible practice test, loss of privacy and genetic discrimination. Details of the decision, and that Myriad OncorMed about their testing services, and how these two companies have addressed the concerns of those outside the company. "Hide
by Margaret L. Eaton, Rebecca Farkas, Daniel Greenwald Source: Stanford Graduate School of Business 30 pages. Publication Date: 01 May 2005. Prod. #: BME3-PDF-ENG
Related Case Solutions & Analyses:
Brooke Correll and Clos Du Val: Adventures in Napa Valley (C)
Appalachian Mountain Club: Transforming Governance
Ekohealth: Developing Price Structures
NBCUniversal
Cree Inc.: Introducing the LED Light Bulb
Leanwashing: A Hidden Factor in the Obesity Crisis
Sustaining Competitive Advantage
Rebranding Gallagher
TripAdvisor, Chinese Version
The Hunger Games: Catching Fire: Using Digital and Social Media for Brand Storytelling
